Anteris Technologies CEO, Wayne Paterson presents at the Annual General Meeting (AGM) held on the 29th May 2024 in Sydney.
Discover how Anteris Technologies plans to bring its highly differentiated, first in class (biomimetic) valve to market, to benefit aortic stenosis patients.
Anteris Technologies proudly stands as Australia’s first and only structural heart company dedicated to transcatheter aortic valve replacement (TAVR). Our commitment to scientific advancement drives us to lead the charge in addressing critical challenges encountered by physicians and patients through pioneering research, development, and delivery of innovative, cutting-edge solutions such as DurAVR™, which represents a new class of biomimetic TAVR.
#asx #asxavr #aorticstenosis #duravr #anteristech
5 окт 2024
